IJMS, Vol. 24, Pages 10196: Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers

IJMS, Vol. 24, Pages 10196: Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers

International Journal of Molecular Sciences doi: 10.3390/ijms241210196

Authors: Fotios Drakopanagiotakis Philipp Markart Paschalis Steiropoulos

Interstitial lung diseases (ILDs) are a large group of pulmonary disorders characterized histologically by the cardinal involvement of the pulmonary interstitium. The prototype of ILDs is idiopathic pulmonary fibrosis (IPF), an incurable disease characterized by progressive distortion and loss of normal lung architecture through unchecked collagen deposition. Acute exacerbations are dramatic events during the clinical course of ILDs, associated with high morbidity and mortality. Infections, microaspiration, and advanced lung disease might be involved in the pathogenesis of acute exacerbations. Despite clinical scores, the prediction of the onset and outcome of acute exacerbations is still inaccurate. Biomarkers are necessary to characterize acute exacerbations better. We review the evidence for alveolar epithelial cell, fibropoliferation, and immunity molecules as potential biomarkers for acute exacerbations of interstitial lung disease.